Risk for Glaucoma Reduced With CGRP Inhibitor Use for Prevention of Migraine

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 11, 2026.

via HealthDay

MONDAY, May 11, 2026 -- For adults with migraine receiving preventive treatment, use of calcitonin gene-related peptide inhibitors (CGRPi) is associated with a reduced risk for glaucoma, according to a study published online May 6 in Neurology.

Chien-Chih Chou, Ph.D., from the National Yang Ming Chiao Tung University in Taipei, Taiwan, and colleagues conducted a multinational retrospective cohort study involving adults diagnosed with migraine who received migraine preventive medications in 2018 to 2024. Participants were categorized into the CGRPi group and the non-CGRPi group; the groups were propensity score-matched in a 1:1 ratio and followed for up to three years for incident glaucoma.

The final analysis included 73,644 individuals. The researchers found that CGRPi users experienced a lower risk for glaucoma development within three years since the first prescription compared with non-CGRPi users (hazard ratio, 0.75). Individuals using CGRPi also had a reduced risk for glaucoma compared with those using topiramate, valproate, propranolol, metoprolol, lisinopril, amitriptyline, and venlafaxine (hazard ratios, 0.73, 0.54, 0.76, 0.76, 0.49, 0.69, and 0.68, respectively). A reduced risk for glaucoma was only seen for users of monoclonal antibody CGRPi compared with non-CGRPi users in an analysis based on the specific CGRPi used (hazard ratio, 0.77). Older adults, women, and those with chronic migraine or migraine without aura had a reduced risk for glaucoma associated with CGRPi use.

"Since CGRP inhibitors help regulate blood vessel contraction and inflammation in the nervous system, there has been hope that these drugs could benefit eye health in people at risk of glaucoma," coauthor Chien-Hsiang Weng, M.D., M.P.H., from Brown University in Providence, Rhode Island, said in a statement.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-12 02:42

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords